Title : Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.

Pub. Date : 2011 Jan

PMID : 20152998






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Metformin has been reported to inhibit DPP-4. Metformin dipeptidyl peptidase 4 Homo sapiens
2 Mean AUC for plasma DPP-4 activity was lower after Metformin + GLP-1 (1505 +- 2 mumol/[mL min], P < .001) and Metformin (1508 +- 2 mumol/[mL min], P < .002) compared with GLP-1 (1587 +- 3 mumol/[mL min]). Metformin dipeptidyl peptidase 4 Homo sapiens
3 Mean AUC for plasma DPP-4 activity was lower after Metformin + GLP-1 (1505 +- 2 mumol/[mL min], P < .001) and Metformin (1508 +- 2 mumol/[mL min], P < .002) compared with GLP-1 (1587 +- 3 mumol/[mL min]). Metformin dipeptidyl peptidase 4 Homo sapiens
4 In patients with type 2 diabetes mellitus, metformin inhibits DPP-4 activity and thus increases active GLP-1 concentrations after subcutaneous injection. Metformin dipeptidyl peptidase 4 Homo sapiens